<?xml version='1.0' encoding='utf-8'?>
<document id="25776278"><sentence text="In vitro inhibition and induction of human cytochrome P450 enzymes by SIPI5357, a potential antidepressant." /><sentence text="This study investigated the in vitro drug-drug interaction potential of SIPI5357, an arylalkanol-piperazine derivative used in the treatment of depression"><entity charOffset="72-80" id="DDI-PubMed.25776278.s2.e0" text="SIPI5357" /><entity charOffset="85-107" id="DDI-PubMed.25776278.s2.e1" text="arylalkanol-piperazine" /><pair ddi="false" e1="DDI-PubMed.25776278.s2.e0" e2="DDI-PubMed.25776278.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25776278.s2.e0" e2="DDI-PubMed.25776278.s2.e1" /></sentence><sentence text=" Drug-drug interaction occurs via inhibition or induction of enzymes involved in their metabolism" /><sentence text=" In human liver microsomes, SIPI5357 showed the strongest inhibition of CYP2D6, followed by CYP3A4 (testosterone) and CYP2C8"><entity charOffset="100-112" id="DDI-PubMed.25776278.s4.e0" text="testosterone" /></sentence><sentence text=" Inhibition was observed in a concentration-dependent manner, with IC50 values of 18" /><sentence text="45 µM, 36" /><sentence text="63 µM (CYP3A4/testosterone), 89"><entity charOffset="14-26" id="DDI-PubMed.25776278.s7.e0" text="testosterone" /></sentence><sentence text="23 µM, respectively" /><sentence text=" SIPI5357 was predicted not to cause significant metabolic drug-drug interaction via inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2E1 or CYP3A4 (midazolam) because the IC50 values for these enzymes were both &gt;100 µM (200 times maximum plasma concentration [Cmax ])" /><sentence text=" SIPI5357 showed a mixed model inhibition of CYP2D6 (Ki = 11" /><sentence text="12 µM)" /><sentence text=" The value of [I]/Ki for CYP2D6 inhibition by SIPI5357 is below the FDA cut-off value of 0" /><sentence text="1; it is therefore reasonable to assume that SIPI5357 will not cause significant CYP2D6 inhibition" /><sentence text=" However, positive controls (50 µM omeprazole and 25 µM rifampin) caused the anticipated CYP induction, but the highest concentration of SIPI5357 (5 µM; 10 times plasma Cmax ) had a minimal effect on CYP1A2 and CYP3A4 mRNA levels in freshly isolated human hepatocytes, suggesting that SIPI5357 is not an inducer of these enzymes"><entity charOffset="35-45" id="DDI-PubMed.25776278.s14.e0" text="omeprazole" /><entity charOffset="56-64" id="DDI-PubMed.25776278.s14.e1" text="rifampin" /><pair ddi="false" e1="DDI-PubMed.25776278.s14.e0" e2="DDI-PubMed.25776278.s14.e0" /><pair ddi="false" e1="DDI-PubMed.25776278.s14.e0" e2="DDI-PubMed.25776278.s14.e1" /></sentence><sentence text=" However, significant induction of CYP2B6 was observed at 0" /><sentence text="5 µM and 5 µM" /><sentence text=" In conclusion, SIPI5357 might cause drug-drug interaction via induction of CYP2B6" /><sentence text=" The in vivo drug-drug interaction potential deserves further investigation" /><sentence text=" Copyright © 2015 John Wiley &amp; Sons, Ltd" /><sentence text="" /></document>